117
Participants
Start Date
October 31, 2013
Primary Completion Date
June 30, 2015
Study Completion Date
May 31, 2016
Regorafenib
Regorafenib will be given 160mg once daily for 3 weeks, followed by a 1 week rest. Treatment will be continued until disease progression or unacceptable toxicity occurs. Response evaluation (CT scans) will be performed every 2 cycles.
Seoul National University Hospital, Seoul
Collaborators (1)
Bayer
INDUSTRY
Seoul National University Hospital
OTHER